leadf
logo-loader
viewOutlook Therapeutics

Outlook Therapeutics' wet AMD therapy study results validates expectations, looks forward to Phase 3

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CEO Lawrence Kenyon tells Proactive the clinical-stage biopharmaceutical company says its ONS-5010 therapy to treat wet AMD revealed positive proof-of-concept results.

Kenyon says investors should understand that this small, 60-patient clinical study was not expected to achieve statistical significance, however, its pivotal NORSE 2 pivotal trial will reveal these results.

Quick facts: Outlook Therapeutics

Price: 0.6957 USD

NASDAQ:OTLK
Market: NASDAQ
Market Cap: $88.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Luminex Resources CEO says stay tuned for drill results out of its Condor...

Luminex Resources Corp. (TSXV: LR) (OTCQX: LUMIF) CEO Marshall Koval tells Proactive the Vancouver-based mining company is making progress on its Condor Gold-Copper Project in Zamora-Chinchipe Province, southeast Ecuador. Koval says the group has advanced metallurgy at the site, continuing to...

16 hours, 37 minutes ago

2 min read